NewAmsterdam Pharma resurrects Amgen's old CETP drug with plans to jump into PhIII this year
Eli Lilly thought it found the “holy grail” a decade ago with a CETP inhibitor that lowered bad cholesterol and raised good cholesterol, with others like Merck, Amgen, Roche and Pfizer jumping in the race as well. But when study after study showed the new class of drugs didn’t curb cardiovascular disease, Big Pharma largely abandoned their efforts.
NewAmsterdam Pharma CEO Michael Davidson saw an opportunity last year to resurrect Amgen’s old drug — one of the few that didn’t make it to pivotal studies. And on Wednesday, he unveiled the first positive Phase II results.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
